Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Venetoclax & azacitidine for AML in 2020

Paresh Vyas • 1 Dec 2020
ASH 2020
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Azacitidine Venetoclax
VIALE-A

Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, discusses the use of venetoclax and azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Paresh Vyas, MRCP, FRCP, FRCPath, has been on advisory boards for Gilead and Agios.

More from Paresh Vyas

2:45
Promising emerging therapies for AML and the challenges that remain
Paresh Vyas • 18 Dec 2023
6:11
First-in-human study of the menin-KMT2A inhibitor JNJ-75276617 in R/R acute leukemias
Paresh Vyas • 18 Dec 2023
1:12
Understanding genetic and non-genetic mechanisms involve in AML disease progression
Paresh Vyas • 24 Apr 2023
0:49
Treatment avenues for patients with R/R FLT3-mutated AML: optimizing FLT3 inhibitors
Paresh Vyas • 24 Apr 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals